A total of 28 patients with advanced solid tumors, including three colon tumor patients, were enrolled in a two-center, open-label, phase I study, and the results showed that the application of the combination of bromohydrin pyrophosphate (IPH1101) and a low-dose of IL-2 was safe and well-tolerated in antitumor immunotherapy, which could effectively induce the expansion of γδ T cells in tumor patients, and the degree of expansion depended on the concentration of IPH1101 (92). Here, IL2 is linked to colonic neoplasm.